| Name | Title | Contact Details |
|---|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Helsinn Therapeutics (US) is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novan, Inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide`s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. We believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
Nventa Biopharmaceuticals Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.